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2014, accepted Feigniﬁcant mitral regurgitation (MR) is frequent in patients with severe aortic stenosis (AS). In these cases,
concomitant mitral valve repair or replacement is usually performed at the time of surgical aortic valve replacement
(SAVR). Transcatheter aortic valve replacement (TAVR) has recently been considered as an alternative for patients at
high or prohibitive surgical risk. However, concomitant signiﬁcant MR in this setting is typically left untreated. Moderate
to severe MR after aortic valve replacement is therefore a relevant entity in the TAVR era. The purpose of this review is
to present the current knowledge on the clinical impact and post-procedural evolution of concomitant signiﬁcant MR in
patients with severe AS who have undergone aortic valve replacement (SAVR and TAVR). This information could
contribute to improving both the clinical decision-making process in and management of this challenging group of
patients. (J Am Coll Cardiol 2014;63:2643–58) ª 2014 by the American College of Cardiology FoundationAortic stenosis (AS) is the most prevalent valvular heart
disease referred for treatment, and it is frequently associated
with concomitant mitral regurgitation (MR) (1). Surgical
aortic valve replacement (SAVR) is the standard treatment
for symptomatic severe AS, and there is a general consensus
that in the presence of severe MR, a double-valve operation
is indicated (2,3). If MR is moderate, the decision of
whether to perform a mitral intervention at the time of
SAVR has to be carefully evaluated, given that a double-
valve operation is associated with increased operative
mortality (4,5). Although MR severity may decrease after
isolated SAVR, it may not improve or even worsen in a
substantial proportion of patients, and a subsequent mitralHeart & Lung Institute, Quebec City, Quebec, Canada; and the
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bruary 25, 2014.valve procedure is associated with increased operative risk in
such cases (6).
Transcatheter aortic valve replacement (TAVR) has recently
emerged as an alternative to SAVR or medical treatment for
patients at high or prohibitive surgical risk, respectively (7).
Concomitant signiﬁcant MR in this setting is typically left
untreated. The persistence of moderate to severe MR after
TAVR is therefore a relatively new and important entity. The
objective of this systematic review is to present the current state
of knowledge on the prevalence, clinical impact, and evolution
of concomitant signiﬁcantMR in patients with severe AS who
have undergone aortic valve replacement (AVR) (SAVR and
TAVR). For this purpose, a literature search using PubMed,
EMBASE, the Cochrane Library, and Internet-based sources
of information on clinical trials (ClinicalTrials, tctmd, and
theheart) was performed from November 2002 to September
2013using “surgical, transcatheter, percutaneous, transfemoral,
transapical aortic valve implantation, replacement and/or
insertion, and mitral regurgitation and/or insufﬁciency” as
subject headings.
Mitral Regurgitation Etiology, Mechanisms,
and Assessment
There are multiple causes of MR, and a speciﬁc cause
might induce regurgitation by different mechanisms
Abbreviations
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AVR = aortic valve
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HR = hazard ratio
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2644(Online Table 1). The mecha-
nisms of MR are usually classiﬁed
as organic (valve structurally ab-
normal) or functional (mitral valve
is structurally normal, and the
leaﬂet coaptation deﬁcit is deter-
mined by ventricular remodeling)
(8). The most common cause of
organic MR is degenerative MR
from myxomatous processes, or
particularly in the elderly, calciﬁ-
cation of the mitral apparatus.
The most common cause of func-
tional MR is ischemic cardiomy-
opathy, where the normal leaﬂets
have a restricted motion, driven
by tethering because of outward
displacement of the left ventric-ular (LV) walls and papillary muscles. LV wall motion ab-
normalities may be focal, with a preserved ejection fraction,
or global with various degrees of LV systolic dysfunction,
geometry changes, and annular dilation. The variable com-
bination of these factors involved in functional MR genesis
can explain the heterogeneous response in MR evolution after
a given intervention. In addition, a combination of MR
etiologies can be seen in many elderly patients with coronary
artery disease or cardiomyopathy. Although the concentric
LV remodeling seen in isolated compensated AS is not
typically associated with functional MR, various factors can
inﬂuence the presence and severity of functional MR in this
population, including the high prevalence of coronary artery
disease with subsequent ischemic MR, the LV dilation seen
in end-stage AS, and/or with associated aortic regurgitation.
The marked increase in the LV-left atrial pressure gradient
associated with severe AS can also contribute to increase the
driving force through the regurgitant oriﬁce area. Hence, the
possibility of mixed etiologies has to be taken into consid-
eration when evaluating MR severity and its potential
regression after AVR.
The echocardiographic evaluation of the severity of MR is
complex, and the integration of various echocardiographic
methods, including quantitative measurements, is recom-
mended in clinical practice (Online Table 2) (2,3,9). An
effective regurgitant oriﬁce is less variable compared with
regurgitant volume in the presence of increased afterload,
and it should therefore be systematically measured in cases of
AS with concomitant MR. In addition, the parameters and
the prognostic implication of a similar degree of volume
overload vary depending on the MR etiology and the un-
derlying LV substrate (Online Table 2) (10,11). In particular,
an effective regurgitant oriﬁce area 0.2 cm2 and a regur-
gitant volume 30 ml/beat have been associated with poorer
outcomes in the context of functional ischemic MR (11), but
functional MR with a regurgitant oriﬁce area between 0.2 and
0.4 cm2 can be graded as severe in the presence of other
echocardiographic signs of regurgitation severity.SAVR in the Presence of Signiﬁcant MR
Most surgical studies to date have focused on single valve
disease; data on multivalve disease are scarce (12). The
European and American guidelines on the management of
valvular heart disease do not provide speciﬁc recommenda-
tions for the management of multivalvular disease (2,3).
There is a general consensus that a double-valve intervention
should be performed in the presence of severe MR, espe-
cially in cases of organic etiology. However, the surgical
management of moderate to severe functional MR in the
setting of severe AS remains controversial.
Double mitral and aortic valve surgeries have been asso-
ciated with a higher mortality rate compared with isolated
SAVR (4,5,13–15). In the Euro Heart Survey on Valvular
Heart Disease, perioperative mortality in patients with
multivalve surgery was 6.5% compared with 2.7% for iso-
lated SAVR and 4.3% for SAVR combined with coronary
artery bypass grafting (4). The latest report of the Society of
Thoracic Surgeons (STS) showed a rate of 3.5% for double-
valve surgery in the past decade (5). Although the ratio of
double-valve interventions/SAVR has decreased slightly in
the last few years, the total number of double-valve pro-
cedures has constantly increased over the last decade (Online
Fig. 1). The perioperative mortality after mitral-aortic valve
replacement ranged from 8.2% to as much as 11%, whereas
the mortality rate after isolated SAVR was between 2.3%
and 3.5% (5).
The decision to intervene in MR in the setting of severe
AS depends on the severity and the etiology of MR.
Although no series of patients with severe MR left untreated
at the time of SAVR have been reported, and a higher
perioperative mortality has been associated with double-
valve interventions, combined aortic and mitral valve sur-
gery seems to be justiﬁed in the presence of severe MR
(either functional or organic) (12). Although retrospective
studies have suggested better outcomes with MR repair
versus replacement for ischemic MR (16), this has not been
conﬁrmed in a recent randomized trial (17). The use of
mitral valve repair techniques is preferred for organic MR,
when feasible, due to lower perioperative mortality,
improved survival, and better preservation of post-operative
LV function (3). However, mitral valve repair options may
be very limited in the presence of rheumatic lesions, severe
valve prolapse, or extensive leaﬂet or annulus calciﬁcation
(18). When repair is not possible, mitral valve replacement
with preservation of the subvalvular apparatus is recom-
mended. However, valve replacement can be difﬁcult and of
high risk in the presence of severe annular calciﬁcation, and
this may be a further incentive not to intervene on the mitral
valve in such cases.
There is still some controversy regarding the optimal
surgical strategy when signiﬁcant MR is less than severe.
Although data about moderate organic MR left untreated at
the time of SAVR is very limited (19,20), most investigators
support a double-valve operation (21). Barreiro et al. (19)
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2645reported a higher cumulative mortality in patients with
moderate MR (severe MR was excluded) in a series of 63%
of patients with organic MR. In the PARTNER (Placement
of Aortic Transcatheter Valve) trial, 59 of the 299 patients
who underwent isolated SAVR had more than mild MR
(moderate: 90.5%, severe: 9.5%; no data on MR etiology
available). There was a trend toward a higher 30-day mor-
tality in patients with signiﬁcant (moderate or severe) MR
(13.6% vs. 7.1%; p ¼ 0.10), and the mortality rate at 2-year
follow-up was also higher in this group (49.1% vs. 27.9%;
p <0.01) (20). Furthermore, moderate or severe MR was an
independent predictor of 2-year mortality in the multivariate
analysis (hazard ratio [HR]: 1.77; 95% conﬁdence interval
[CI]: 1.17 to 2.68) (22).
In patients with moderate MR of functional origin who
underwent SAVR, the debate of whether or not to perform
mitral intervention continues (21,23). Some investigators
support a conservative approach in such cases (24–27), but
others suggest a double-valve intervention because of the
lack of improvement in MR severity in approximately one-
half of the patients after isolated SAVR and the negative
impact of concomitant MR on early and late mortalityTable 1 Impact of Signiﬁcant Mitral Regurgitation on Mortality in Pa
First Author, Year (Ref. #) N Etiology Grade of MR
Ea
Mor
Absil, 2003* (26) 116 FMR 100%
58 0–1 3
58 2–3y 7
Moazani, 2004 (28) 107 FMR 100%
72 1–2 (trivial–mild)
35 3–4 (moderate–severe)
Barreiro, 2005 (19) 408 FMR 37.1%
338 No/mild 3
70 Moderatey 7
Ruel, 2006 (29) 706 FMR 100%
630 0–1 N
76 2 N
2 þ RFz
Caballero-Borrego, 2008 (30) 572 FMR 100%
419 No MR 5
153 Non-severe MRy 10
Wan, 2009* (27) 182 FMR 100%
91 0–1 N
91 2 N
Takeda, 2010 (31) 193
134 No/trivial (0–1) 2
59 Mild/moderate (2–3)y 1
Partner A, 2012 (20) 299 NA
240 None/mild 7
59 Moderate/severe 13
Coutinho, 2013 (32) 255 FMR 100%
161 B >2 Untreated 0
94 >2 with surgical treatment 1
Values are n, %, or mean  SD. *Case-matched study. yGrade 4 or severe mitral regurgitation (MR) ex
(peak <60 or mean <40 mm Hg) or atrial ﬁbrillation. xIncidence of the composite endpoint, including
CI ¼ conﬁdence interval; FMR ¼ functional mitral regurgitation; HR ¼ hazard ratio; NA ¼ not applica(28–31) (Table 1). Although 2 case-matched studies
(26,27), and more recently, Takeda et al. (31) showed no
impact of signiﬁcant MR on mortality after SAVR, other
studies (28–30) reported an increase in perioperative com-
plications and/or mortality in the presence of signiﬁcant
MR. The variability in the design and inclusion criteria
among studies may partially explain these contrasting results.
Patients with functional severe MR were included in some
studies (11,12,14,20,27–29), but not in others (26,30,31),
and some studies included patients with nonsigniﬁcant
(trivial or mild) MR in the concomitant MR group (30).
Coutinho et al. (32) evaluated the impact of mitral inter-
vention in patients with functional moderate MR on survival
in the setting of SAVR. Although late mortality was not
inﬂuenced by the decision of MR intervention, patients who
underwent combined mitral and aortic surgery experienced
more pronounced reverse LV remodeling and less congestive
heart failure symptoms (New York Heart Association
functional [NYHA] functional classes III to IV). More
importantly, the lack of improvement in MR severity over
time was associated with late mortality in multivariate
analysis (HR: 4.90, 95% CI: 1.92 to 12.60; p ¼ 0.001).tients Undergoing Isolated Surgical Aortic Valve Replacement
rly
tality p Value Follow-Up (yrs)
Cumulative
Survival p Value
Multivariate Analysis
HR (95% CI)
3.2  2.4
.5% 0.67 (8) 60.9% 0.10 NA
.0% 55.0%
5
89.1% 0.04
71.4%
10
.8% 0.21 40.1% 0.04 1.43 (1.03–1.98)
.1% 14.6%
5.4  3.2
A (10)
A 2.7 (1.5–4.7) 1.8 (0.9–3.4)
0.02 2.7 (1.4–5.4)x
NA
.6% 0.02 NA
.5% NA
10
A 43.4% 0.33 NA
A 48.3%
3.3  0.5
.9% 0.60 (10) 90.3% 0.49 NA
.7% 88.0%
2
.1% 0.09 28.1% 0.04 1.77 (1.17–2.68)
.6% 49.8%
10
.0% 0.19 66.6% 0.44 NA
.1% 76.7%
cluded. zOne of the following risk factors: left atrial size >5 cm, low preoperative aortic gradient
heart failure symptoms, heart failure death, and mitral valve surgery.
ble/available; RF ¼ risk factor.
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2646Incidence and Etiology of MR in
Patients Who Underwent TAVR
The prevalence and severity of MR in patients included in
several TAVR registries and the PARTNER trial are shown
in Figure 1 (33–41). The rate of concomitant moderate to
severe MR in this population ranges between 2% and 33%.
Of note, quantitative methods, such as regurgitant volume
and effective regurgitant oriﬁce for the assessment of MR,
were not systematically used. Some studies, such as the
SOURCE (SAPIEN Aortic Bioprosthesis European
Outcome) registry, reported the rate (25.2%), but not the
severity of concomitant mitral valve disease (42). Also,
although the severity of MR was classiﬁed in 4 grades (from
1 to 4) in some studies, others used a 3 grade classiﬁcation
(mild, moderate, and severe). Overall, the rate of 3/4 or
severe MR was systematically <10% (33,35–38,40,41).
However, if patients with 2/4 or moderate MR were
included, the incidence increased up to approximately 20%.
The PARTNER trial reported an incidence of moderate
to severe MR of 19.8% and 22.2% in cohorts A and B,
respectively (35,36). In a recent analysis, severe MR was
present in 3.8% of TAVR patients (from cohorts A and B
together) after evaluation from a central echocardiography
core laboratory, even when severe MR was a pre-speciﬁed
exclusion criterion in the trial (20).Figure 1 Incidence of Signiﬁcant Mitral Regurgitation in Patients Un
Incidence of moderate to severe mitral regurgitation across the national TAVR registries an
valve replacement; TF ¼ transfemoral.Only a few studies have provided data on the etiology
of MR in patients who have undergone TAVR (Fig. 2)
(41,43–49). Although organic MR is usually more frequent
than functional MR in the general population (8), func-
tional MR accounts for approximately 50% of patients with
MR in patients who have undergone TAVR. This may be
related to a patient selection bias secondary to the belief
that functional, but not organic, MR is likely to improve
after TAVR. As previously mentioned, no study to date has
reported the incidence of mixed MR etiologies, which are
probably very frequent among TAVR candidates. Also,
future studies will have to standardize MR evaluation and
severity according to the mechanism and determine its
implications after TAVR.
Impact of Signiﬁcant MR on
Acute Mortality After TAVR
The results of studies evaluating the impact of signiﬁcant
MR on in-hospital or 30-day mortality after TAVR are
summarized in Table 2 (33,39–41,48,50,51). Some studies
suggested an increase in early mortality after TAVR
(33,39–41,48), and others failed to demonstrate this asso-
ciation (20,50,51). Importantly, although some studies
(33,40) included severe MR only, others (20,39,48,50,51)
included moderate or severe MR in the signiﬁcant MRdergoing Transcatheter Aortic Valve Replacement
d the PARTNER trial. SC¼ subclavian; TA ¼ transapical; TAVR ¼ transcatheter aortic
Figure 2 Etiology of Mitral Regurgitation in Patients Undergoing Transcatheter Aortic Valve Replacement
Percentage of patients with organic and functional mitral regurgitation across transcatheter aortic valve replacement studies.
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2647group. This might partially explain differences in the acute
clinical impact of MR among studies. A global weighted
analysis with the published data revealed that patients with
signiﬁcant (moderate or severe) MR experienced higher
early mortality (odds ratio [OR]: 1.49, 95% CI: 1.12 to 2.00;
p ¼ 0.004; heterogeneity test ¼ 0.006) (Table 2). However,
no studies to date reported the mortality rate according to
the MR etiology (functional or organic). Whether this in-
crease in early mortality depends on MR etiology has to be
determined in future studies.
The presence of signiﬁcant MR may increase patients’
vulnerability with regard to periprocedural hemodynamic
changes and/or complications. Any complication leading
to hemodynamic instability may rapidly decompensate
the hemodynamic status of the patient, leading to a re-
fractory heart failure and cardiogenic shock. Caballero-
Borrego et al. (30) showed that concomitant MR before
SAVR was associated with a higher rate of low output
during the immediate post-operative period. Signiﬁcant
MR has also been associated with an early risk of
decompensated heart failure and mortality after cardiac
and noncardiac surgery (32,52,53). In accordance with
these data, those patients with severe MR in the Italian
TAVR registry experienced more hospitalization due to
heart failure within the ﬁrst month (41). Thus, patients
with MR constitute a population with poorer hemody-
namic reserve. A meticulous ﬂuid balance and afterload
reduction are essential, especially during the immediate
post-operative period. In addition, MR often leads to
pulmonary hypertension, which, in turn, has been asso-
ciated with poorer outcomes after cardiac surgery and
TAVR (34,41,54–56).Impact of Signiﬁcant MR on
Late Mortality After TAVR
Several studies have identiﬁed the presence of concomi-
tant moderate-to-severe MR as an independent predictor
of mid-term mortality after TAVR (Table 2). The
German and the Italian TAVR registries showed that the
presence of moderate or 2 MR was a strong predictor
of 1-year mortality, and this prognostic value persisted
after a landmark analysis at 1 month (excluding 30-day
events) (38,41). In addition, both registries found an
incremental risk associated with increasing grades of
MR severity, similar to other cardiac diseases (11,57).
Furthermore, the Italian registry reported an increased
risk in cardiac mortality in patients with moderate
MR. The FRANCE 2 and the Spanish TAVR registries
also found an association between signiﬁcant MR and
mortality at 1-year follow-up in the univariate analysis,
but only a trend toward higher mortality after adjustment
for other confounding variables in the multivariate
analysis (40,58). Unlike these results, patients with
moderate to severe MR included in the PARTNER
trial (TAVR cohort) had similar mortality rates compa-
red with the patients with no or mild MR (20).
Weighted analysis with all the studies revealed a higher
cumulative mortality in patients with signiﬁcant MR
(OR: 1.44, 95% CI: 1.23 to 1.68; p <0.001; heteroge-
neity test ¼ 0.019) (Table 2).
The presence of MR has been identiﬁed as a prognostic
marker in the setting of acute coronary syndromes (59–61),
surgical (62) and percutaneous coronary interventions (63),
chronic heart failure (57,64,65), and cardiomyopathies (66).
Table 2 Impact of Moderate to Severe Mitral Regurgitation in Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement
First Author, Year (Ref. #) N Grade of MR
Univariate Analysis
OR/HR (95% CI)
Multivariate Analysis
OR/HR (95% CI)
In-hospital or 30-day mortality
Rodés-Cabau, 2010 (33) 339 Severe: 27 (8.0%) 2.40 (1.04–5.56),
p ¼ 0.049
3.01 (1.09–8.24), p ¼ 0.033
Toggweiler, 2012 (48) 451 Moderate: 132 (29.3%) 2.04 (1.11–3.74),
p ¼ 0.02
2.10 (1.12–3.94), p ¼ 0.02
D’Onofrio, 2012 (50) 176 2: 43 (24.4%) 9.3% vs. 3%,
p ¼ 0.10
d
Hutter, 2013 (51) 268 Moderate: 60 (22.4%) 13.3% vs. 9.6%,
p ¼ NA
d
Di Mario, 2013 (39)y 4,571 2: (20.8%) d 1.45 (1.08–1.93), p ¼ 0.010*
Sabaté, 2013 (40) 890 3: 55 (6.2%) 3.28 (1.87–5.76),
p ¼ 0.001
4.12 (1.99–8.5), p ¼ 0.001*
Bedogni, 2013 (41) 1,007 Moderate: 243 (24.1%)
Severe: 94 (9.3%)
11% vs. 9% vs. 5%,
p ¼ 0.006
2.2 (1.78–3.28), p ¼ 0.001
1.9 (1.1–3.3) p ¼ 0.02
Barbanti, 2013 (20) 499 Moderate: 103 (20.6%) 3.9% vs. 6.1%
p ¼ 0.41
d
Overall (weighted analysis) 3,956 1.49 (1.12–2.00)
p ¼ 0.004z
Late (>30-day) mortality
Rodés-Cabau, 2010 (33) 339 Severe: 27 (8.0%) d 10.7% vs. 7.2%,
p ¼ 0.447
Toggweiler, 2012 (48) 451 Moderate: 132 (29.3%) 0.94 (0.58–1.51),
p ¼ 0.80
0.82 (0.50–1.34), p ¼ 0.42
Zhan, 2013 (38) 1,391 2: 42 (3.2%) d 1.70 (1.19–2.42), p ¼ 0.003x
Bedogni, 2013 (41) 1,007 Moderate: 243 (24.1%)
Severe: 94 (9.3%)
17% vs.12% vs. 10%,
p ¼ 0.01
1.7 (1.2–3.41), p ¼ 0.001
1.4 (1.2–2.2), p ¼ 0.03
Late cumulative mortality
Leon, 2010 (35) 171 Moderate: 38 (22.2%) 23.7% vs. 32.3%,
p ¼ 0.307
d
Tamburino, 2011 (34)y 663 3–4: 42 (6.3%) 35.7% vs. 15.9%,
p ¼ 0.001
4.62 (1.66–12.87), p ¼ 0.003
Smith, 2011 (36) 334 Moderate: 66 (19.8%) 24.2% vs. 24.6%,
p ¼ 0.948
d
D’Onofrio, 2012 (50) 176 2: 43 (24.4%) 22% vs. 25%,
p ¼ 0.21
d
Van Belle, 2012 (58) 3,195 0: 1183 (37.0%)
1: 1351 (42.3%)
2: 661 (20.7%)
24% vs. 20.1% vs. 15.8%,
p ¼ 0.002
1.16 (0.94–1.42),
1.09 (0.85–1.40), p ¼ 0.39
Zhan, 2013 (38) 1,391 2: 42 (3.2%) 5.7% vs. 2.5%,
p ¼ 0.009
1.57 (1.22–2.02), p ¼ 0.001
Hutter, 2013 (51) 268 Moderate and severe:
60 (22.4%)
30.2% vs 21.2%,
p ¼ 0.068
d
Sabaté, 2013 (40) 890 3: 55 (6.2%) 2.63 (1.58–4.36),
p ¼ 0.001
1.67 (0.94–2.96), p ¼ 0.09
Bedogni, 2013 (41) 1,007 Moderate: 243 (24.1%)
Severe: 94 (9.3%)
25% vs. 20% vs. 15%,
p ¼ 0.02
2.9 (2.5–3.8), p ¼ 0.001
Overall (weighted analysis) 6,734 1.44 (1.23–1.68)
p <0.001jj
Values are n and %, unless otherwise indicated. *In hospital mortality. yExcluded from the weighted analysis due to repetitive patients from other series. zHeterogeneity test ¼ 0.006. xLate mortality
(discharge to 1 year). jjHeterogeneity test ¼ 0.019.
OR ¼ odds ratio; other abbreviations as in Table 1.
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2648It is therefore not surprising that the presence of moderate
MR has been found to have an impact on long-term
mortality in patients who have undergone TAVR,
commonly an elderly population with several comorbidities
and a high-risk proﬁle. In the presence of signiﬁcant MR,
volume overload continues and maintains LV remodeling,
even after pressure overload correction with TAVR. Pro-
longed hemodynamic overload ultimately leads to heartfailure, which, in turn, translates into poorer outcomes (67).
Interestingly, registries of TAVR predominantly using the
CoreValve (Medtronic, Minneapolis, Minnesota) system
showed that signiﬁcant MR was an independent and
powerful predictor of late mortality (34,38,41), whereas only
a univariate (but not multivariate) association was observed
in registries with approximately 50% use of the CoreValve
system (37,40). No impact on late mortality was observed in
JACC Vol. 63, No. 24, 2014 Nombela-Franco et al.
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2649the studies with a 100% use of balloon-expandable valves
(20,33,48,55). Several studies showed a higher rate of
moderate to severe aortic regurgitation after TAVR with the
CoreValve system (37,68–72), which, in turn, could
adversely affect LV remodeling and increase patients’
vulnerability in the presence of signiﬁcant MR. However,
whether the type of transcatheter heart valve has an inﬂu-
ence on the impact of signiﬁcant MR in TAVR patients
will have to be conﬁrmed in future studies.
A careful assessment of baseline patient characteristics,
the repercussion of all degrees and etiologies of MR on LV
geometry and remodeling, and the determination of the
precise causes of death (cardiovascular vs. noncardiovascular)
in such patients are needed to conﬁrm the nature and real
impact of concomitant MR in patients undergoing TAVR.
In addition, whether or not survival directly correlates with
improvement in MR severity after TAVR remains unclear.
Finally, future studies will have to elucidate the prognostic
value of signiﬁcant MR according to its etiology (organic vs.
functional).
Impact of Signiﬁcant MR on
Functional Status After TAVR
About one-fourth of patients experience no improvement in
their quality of life and/or functional capacity after TAVR
(56,73,74). Among other factors, Gotzmann et al. (56)
found that severe baseline MR was an independent predic-
tor of poor functional response after TAVR, particularly inFigure 3
Transthoracic Echocardiographic Images of Mitral Regurgit
(Patient with Functional Mitral Regurgitation)
Example of mitral regurgitation improvement after transcatheter aortic valve replacement
(A and B) Pre-transcatheter aortic valve replacement. (C and D) Twelve months post-tranpatients with organic MR. However, other studies in the
TAVR ﬁeld have reported an improvement in functional
status similar to that of the nonsigniﬁcant MR group
(20,41,50,51,75). These data, however, must be inter-
preted with caution due to the possibility of a survival bias
(only patients who survived had a functional status evalua-
tion). The combined endpoint of mortality and poor func-
tional response to the treatment may have been higher
among patients with signiﬁcant MR. In addition, NYHA
class has been shown to be inaccurate for the evaluation of
functional improvement and had a poor correlation with
other functional capacity status or quality-of-life tests in
heart failure patients (76,77). Further evaluation of func-
tional capacity with more objective and reliable methods is
therefore needed to determine the real impact of MR after
TAVR.
Changes in MR After AVR (SAVR and TAVR)
The severity of MR results from the complex interaction
among the causal mechanism, the effective regurgitant oriﬁce
area, its dynamic behavior during the cardiac cycle, and the
magnitude of the systolic pressure gradient between the LV
and the left atrium (78). In patients with severe AS and
concomitant signiﬁcant MR, several physiological changes
occur after aortic ﬂow restoration, which, in turn, could
contribute to reducing MR severity (Fig. 3). LV cavity pres-
sure drops very early after AVR, and consequently, the
transmitral pressure gradient may decrease, resulting in aation Pre- and Post-Transcatheter Aortic Valve Replacement
as assessed by transthoracic echocardiography in parasternal and 4-chamber views.
scatheter aortic valve replacement.
Figure 4 Changes in Moderate Mitral Regurgitation (Functional Etiology) After Surgical Aortic Valve Replacement
Percentage of patients with improvement or unchanged mitral regurgitation after surgical aortic valve replacement.
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2650reduction inMR in most patients. However, in some patients
with functional MR, the decrease in the transmitral gradient
may lead to reduction in the mitral valve closing forces, and
therefore, persistence of MR. In the late post-operative
period, a regression of concentric myocardial hypertrophy
due to a decrease in ventricular afterload has been described
after SAVR (79,80) and TAVR (81), and this, in turn, can
inﬂuence mitral valve hemodynamics. In addition, a reverse
remodeling effect leading to changes in LV shape
and geometry may also contribute to improving functional
MR due to a reduction in LV end-diastolic volume and
mitral tethering forces. Although this mechanism has been
described in the early perioperative period after SAVR (82), it
is more likely to play a role in the long-term improvement of
MR.
A decrease in functional MR severity is common after
isolated SAVR (24–27,30,31). However, some studies have
shown that concomitant MR may not improve in up to one-
half of the patients or even increase after SAVR (6,83–86)
(Fig. 4). In accordance with these results, MR severity
improvement after TAVR has been described in several
studies using both self- and balloon-expandable trans-
catheter heart valves (Table 3; Fig. 5). However, although
some degree of improvement in MR was observed in a
signiﬁcant number of patients in all studies, MR severityremained unchanged or even worsened in at least half of the
patients in most studies (20,42–51,87–89). Importantly,
some studies reported the changes, including all grades of
MR severity (from none to severe) (43–47,81,88), and
others focused only on patients with moderate to severe MR
(20,48–51). Of note, the parameters for MR evaluation
varied across the studies, and this may partially explain the
discrepancies among studies in MR changes after SAVR
and TAVR (9,90).
The factors that have been associated with MR
improvement after AVR (SAVR and TAVR) are listed in
Table 4. The presence of LV dysfunction and MR of
functional origin have been associated with greater im-
provements in MR severity after SAVR (6). In accordance
with these data, the presence of functional MR has been
identiﬁed as 1 important factor that determines MR
improvement after TAVR (41,46,48). The presence of a
poorer LV ejection fraction and larger ventricular diameters
have also been associated with greater improvements in MR
(20,42,43,47). This suggests that identifying a potential for
LV reverse remodeling may be the key when evaluating the
likelihood of MR improvement after AVR. In contrast, in
the presence of degenerated and calciﬁed mitral valve dis-
ease, the regurgitant oriﬁce area may remain unchanged after
successful TAVR (42) (Fig. 6). However, no data exist about
Figure 5 Changes in Mitral Regurgitation After Transcatheter Aortic Valve Replacement
Percentage of patients with improvement, unchanged or worsened mitral regurgitation (MR) after transcatheter aortic valve replacement.
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2651MR changes in patients with mixed (functional and organic)
mitral valve disease. Chronic atrial ﬁbrillation, pulmonary
hypertension, and a larger atrial size have been identiﬁed as
predictive factors of the lack of MR improvement after
SAVR (25,29,30,91,92) and TAVR (41,48). These factors
may reﬂect more advanced MR and/or LV disease and a
lower likelihood of improvement after AS release. In addi-
tion, a lesser degree of MR improvement with the use of the
self-expandable CoreValve system compared with the
balloon-expandable Edwards valve (Edwards Lifesciences,
Irvine, California) has been suggested (49,93). Several fac-
tors could be related to this hypothesis, such as the higher
incidence of new pacemaker implantation, left bundle
branch block, and residual aortic regurgitation with the
CoreValve system (37,69,94,95). LV ventricular dyssyn-
chrony observed during right ventricular pacing and/or in
the presence of left bundle branch block may also adversely
affect MR (96,97). Importantly, it has been suggested that
residual aortic regurgitation may negatively inﬂuence MR
improvement in SAVR (91) and TAVR (98). Although a
deeper implantation of the CoreValve with a potential
interaction of the stent frame and the anterior mitral leaﬂet
was initially described (45), this has not been conﬁrmed by
other studies (41). A higher transvalvular gradient pre-
procedure has also been identiﬁed as an independent pre-
dictor of MR improvement after SAVR and TAVR (29,48),which is probably secondary to a greater reduction in the
systolic atrioventricular gradient after AS release and greater
regression of LV hypertrophy and remodeling. In this re-
gard, the presence of prosthesis–patient mismatch (i.e., re-
sidual AS) has been shown to be associated with lesser
regression of concomitant MR after SAVR (99,100).
Interestingly, TAVR has been associated with a lower
incidence of prosthesis–patient mismatch compared with
SAVR (101), and future studies will have to evaluate
whether this translates into differences in MR improvement
compared with SAVR.
Although the observational nature and the heterogeneity
of the current literature limits drawing deﬁnite conclusions,
it appears that concomitant signiﬁcant MR improves in
approximately 50% of patients after TAVR, especially in
cases with MR of functional etiology. More detailed path-
ophysiological data on the effects of TAVR on MR are
needed to better identify the predictors of improvement and/
or worsening, and to clarify the potential beneﬁt of
improvement with longer clinical follow-up.
Percutaneous Treatment of MR After TAVR
Percutaneousmitral valve repair simulating the surgical “edge-
to-edge” technique with the Mitraclip device (Abbot
Vascular, Abbot Park, Illinois) has been shown to be
Table 3 Changes in Mitral Regurgitation Severity After Transcatheter Aortic Valve Replacement
First Author,
Year (Ref. #)
Valve
Type
Baseline Discharge Follow-Up
Global Changes in
MR Grade % Improved % Worsenedn MR, Etiology n MR n MR Days
Webb, 2007 (87) ES 50 None/trivial: 26%
Mild: 26%
Moderate: 32%
Severe: 16%
42 None/trivial:31%
Mild: 36%
Moderate: 24%
Severe: 9%
29 None/trivial:14%
Mild: 62%
Moderate: 21%
Severe: 3%
180 Median grade 2 to
grade 1 (p ¼ 0.01)
d d
Tzikas, 2010 (43) CV 74 None: 24%
Mild: 57%
Moderate: 18%
Severe: 1%
FMR ¼ 50%
71 None: 28%
Mild: 53%
Moderate: 18%
Severe: 1%
46 None: 22%
Mild: 59%
Moderate: 17%
Severe: 2%
Pre to discharge:
1.91 to 1.89
Pre to follow-up
1.91 to 1.98, p ¼ 0.89
17.4%* 21.7%*
Osten, 2010 (89) ES 46 24% 41 9% 14 <9% 365 d d d
Gotzmann, 2010 (81) CV 39 None: 12.8%
Mild: 38.5%
Moderate: 38.5%
Severe: 10.2%
39 None: 7.7%
Mild: 43.6%
Moderate: 38.5%
Severe: 10.2%
39 None: 12.8%
Mild: 43.6%
Moderate: 33.3%
Severe: 10.2%
180 Pre to discharge:
1.46 to 1.51, p¼ 0.160
Pre to follow-up
1.46 to 1.41, p¼ 0.160
18%y 23%y
Masson, 2010 (88) ES 136 2: 55.9
3: 44.1
d 113 0–2: 69.0%
3: 24.8%
4: 6.2%
30 d 33.6%y 22.1%y
Durst, 2011 (44) ES 55
(34)
Mild: 36.4%
Mild–Moderate: 47%
Moderate: 47%
Severe: 6%
FMR ¼ 18%
28 Mild: 36
Mild–Moderate: 46%
Moderate: 14%
Severe: 4%
26 Mild: 31
Mild–Moderate: 50%
Moderate: 15%
Severe: 4%
180 VC Pre to discharge:
0.5  0.2 to 0.3  0.2,
p <0.001
VC Pre to follow-up:
0.5  0.2 to 0.3  0.2,
p <0.001
22%*z 6.4%x
De Chiara, 2011 (45) CV 58 þ1: 72.4%
þ2: 22.4%
þ3: 3.5%
þ4: 1.7%
FMR ¼ 19%
d 58 þ1: 69.0%
þ2: 17.2%
þ3: 12.1%
þ4: 1.7%
234 Pre to follow-up
1.34 to 1.48, p¼ 0.086
12%* 33%*
Samin, 2011 (46) ES 18  þ1: 33.3%
þ2: 33.3%
þ3: 27.8%
þ4: 5.6%
FMR ¼ 62%
18 þ1: 50.0%
þ2: 22.2%
þ3: 27.8%
þ4: 0%
18 þ1: 50.0%
þ2: 38.9%
þ3: 11.1%
þ4: 0%
30 Pre to discharge:
2.1  0.9 to 1.5  1.1,
p ¼ NA
Pre to follow-up
2.1  0.9 to 1.4  0.9
p <0.05
39%y
(if MR 2, 58%)
0%y
Hekimian, 2012 (47) ES 119 0: 24.4%
þ1:43.7%
þ2: 28.6%
þ3: 2.5%
þ4: 0.8%
FMR ¼ 26%
99 0: 31.3%
þ1: 44.4%
þ2: 23.2%
þ3: 1.0%
þ4: 0%
60 0: 36.7%
þ1: 41.7%
þ2: 18.3%
þ3: 3.3%
þ4: 0%
30 Pre to 7 day:
1.2  0.8 to 0.9  0.8,
p <0.01
7 to 30 day:
0.9  0.8 to 0.9  0.8,
p ¼ 0.182
28%y 11%y
Toggweiler, 2012 (48) ES 451
(132)
Mild: 70.7%
Moderate: 67.4%
Severe: 32.6%
FMR ¼ 56%
123 Mild: 57.7%
Moderate: 27.7%
Severe: 14.6%
94 Mild: 64.9%
Moderate: 26.6%
Severe: 8.5%
365 Pre to discharge:
2.3  0.4 to 1.6  0.7,
p <0.01
Pre to follow-up:
2.3  0.4 to 1.4  0.6,
p <0.01
54.6%* 0.7%*
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2653associated with favorable results compared with medical
therapy in patients with symptomatic severe MR who are
deemed inoperable or at high surgical risk (102,103). The
EVEREST (Efﬁcacy of Vasopressin Antagonism in Heart
Failure: Outcome Study With Tolvaptan) trial demonstrated
the safety of the technique with a very low complication rate
(104). Patients who undergo TAVR and who remain symp-
tomatic due to signiﬁcantMR could potentially beneﬁt from a
staged percutaneous procedure to treat MR. The feasibility of
implanting a Mitraclip device after TAVR with the Edwards
and CoreValve systems was ﬁrst described in 2011 (105,106).
In both cases, the aortic prosthesis did not inﬂuenceMitraclip
implantation. However, there are a lack of data on the clinical
beneﬁts associated with this procedure in the TAVR popu-
lation. Only 2 series with a limited number of patients showed
contrary results in mortality rate and changes in functional
class in the follow-up (107,108). Although Rudolph et al.
(107) reported a 36% mortality rate at 7-month follow-up,
Kische et al. (108) showed a signiﬁcant improvement in
functional status after a percutaneous mitral repair procedure
in 12 patients with persistent severe MR after TAVR at 6-
month follow-up.
Currently, experience with percutaneous mitral valve
repair after TAVR is scarce, but it seems to be technically
feasible and may be a therapeutic option in the future for
nonresponder patients. In contrast to the increased risk
associated with a second stage surgery, previous TAVR does
not seem to increase the risk of a subsequent percutaneous
mitral intervention. However, careful patient evaluation and
selection is crucial to better identify those who will derive the
greatest beneﬁt from percutaneous mitral repair.
Management of Concomitant Moderate to
Severe MR in Patients With Severe AS
The management of patients with severe AS and concom-
itant MR is challenging. The decision to intervene in both
valves requires a careful evaluation of the patient’s comor-
bidities and MR etiology and severity by quantitative
echocardiographic methods. Thus, the decision-making
process should be based in the assessment of operative
risk, MR severity, and likelihood of MR improvement after
isolated AVR (Fig. 7). In patients with low or intermediate
surgical risk and moderate to severe MR, appropriate patient
selection is crucial to identify patients in whom MR will not
improve or even progress after SAVR. In those patients with
a low likelihood to improve, the increased risk of a double-
valve procedure may be justiﬁed (assuming an operative
mortality of 6% to 10%). In patients with high surgical risk
in whom SAVR and TAVR are both an option, identiﬁ-
cation of factors associated with improvement may predis-
pose to one or the other treatment. Patients with a high
likelihood of a decrease in MR after the intervention might
be inclined to undergo TAVR, thus avoiding the increased
risk of double-valve intervention, whereas a combined
SAVR with mitral repair and/or replacement would be
Table 4
Predictive Factors Associated With Improvement in Mitral Regurgitation Severity After
Aortic Valve Replacement (Surgical Aortic Valve Replacement and Transcatheter Aortic
Valve Replacement)
Factors Procedure (Ref. #) OR/HR in Multivariate Analysis (Ref. #)
MR etiology (functional vs. organic) SAVR (19,31,86)
TAVR (41,46,48)
HR: 2.6 (1.8–3.1) p <0.01 (41)
HR: 2.6 (1.1–5.9) p ¼ 0.02 (48)
Absence of pulmonary hypertension SAVR (30)
TAVR (41,48)
OR: 3.0 (1.0–10.0) p ¼ 0.05 (30)
HR: 2.9 (2.7–3.3) p <0.01 (41)
HR: 2.7 (1.1–6.6) p ¼ 0.03 (48)
Absence of atrial ﬁbrillation SAVR (29,92)
TAVR (41,48)
p ¼ 0.03 (90)
HR: 2.0 (1.9–2.5) p <0.01 (41)
HR: 2.5 (1.2–5.5) p ¼ 0.02 (48)
LVEF (low vs. normal) and LV diameters SAVR (27)
TAVR (20,42,43,47)
OR: 1.1 (1.0–1.1) p ¼ 0.01(27)
OR: 5.4 (1.2–23.4) p ¼ 0.02* (20)
Mean gradient SAVR (29)
TAVR (48)
HR: 2.7 (1.2–6.2) p ¼ 0.02 (48)
Residual aortic regurgitation SAVR (91)
TAVR (97)
p ¼ 0.01 (91)
Increase left atrial size SAVR (25,29,91) p ¼ 0.03* (25)
p <0.01 (91)
Presence of coronary artery disease
or previous myocardial infarction
SAVR (28,30,84) OR: 5.0 (1.4–18.4) p ¼ 0.01 (28)
OR: 3.7 (1.1–13.0) p ¼ 0.04 (30)
Prosthesis patient mismatch SAVR (98)
Absence of mitral annular calciﬁcation
with restriction
TAVR (44) 17% vs. 61%, p ¼ 0.05* (44)
Valve type (ES vs. CV) TAVR (49) Greater improvement with ES* (49)
Deeper implantation CV TAVR (45) 9.4 vs. 7.6 mm p ¼ 0.02* (45)
Not found in (41)
*Univariate analysis.
LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; SAVR ¼ surgical aortic valve replacement; TAVR ¼ transcatheter aortic valve replacement;
other abbreviations as in Tables 1 to 3.
Figure 6
Transthoracic Echocardiographic Images of Mitral Regurgitation Pre- and Post-Transcatheter Aortic Valve Replacement
(Patient With Organic Mitral Regurgitation)
Example showing the lack of change in mitral regurgitation severity after transcatheter aortic valve replacement as assessed by transthoracic echocardiography in 4- and
2-chamber views. (A and B) Pre-transcatheter aortic valve replacement. (C and D) Six months after transcatheter aortic valve replacement.
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Figure 7 Decisional Algorithm for Management of Patients With Severe Aortic Stenosis and Concomitant Mitral Regurgitation
*Quantitative echocardiography evaluation to differentiate between moderate and severe mitral regurgitation (MR). yMost frequent factors associated with improvement:
absence of atrial ﬁbrillation or pulmonary hypertension, normal atrial size. zAssuming perioperative mortality of 6% to 10%. Several of the recommendations proposed in this
algorithm are based on limited data and will need to be further validated by future studies. SAVR ¼ surgical aortic valve replacement; other abbreviations as in Figure 1.
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2655better in patients with a low likelihood of MR improvement
after TAVR. In patients with very high or prohibitive sur-
gical risk, TAVR is the ﬁrst option, assuming an increase
mortality risk determined by the presence of moderate to
severe MR. However, if MR severity is deemed to be un-
changed or worsened after TAVR, medical treatment should
be considered as an additional option.
Conclusions
Concomitant signiﬁcant MR left untreated at the time of
AVR is an important and frequent entity in the TAVR era.
Moderate to severe MR is common (approximately 20%) in
patients undergoing TAVR, and it has been associated with
higher early and late mortality. Given the limitations (pub-
lications bias and lack of standardized studies) of the current
literature, the nature of this association, as a cause or as a
marker of worse prognosis, has not been yet determined.
MR severity improves in approximately 50% of the patients
after TAVR, especially in those with LV dysfunction and
functional MR. However, future studies with centralized
core laboratories should standardize the evaluation of MR
severity and mechanism to better determine the main pre-
dictors of MR improvement and its impact on mortality.
Identifying the patients with the highest and lowest likeli-
hood for MR improvement is of utmost importance in the
clinical decision-making process, especially in moderate to
high risk but still operable patients who might beneﬁt from a
double (aortic and mitral) surgical therapy. A second staged
percutaneous approach for mitral valve repair with the
Mitraclip device may be an additional option in cases withpersistent severe symptomatic MR after TAVR. However,
more data on the efﬁcacy and safety of Mitraclip implan-
tation in patients who have undergone TAVR is needed.
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